The overall role of the Viral Immunology Core is to provide a standard platform to characterize the properties of new Env genes generated by this HIVRAD program and to evaluate the epitope specificity and neutralization breadth and potency of sera and monoclonal antibodies generated by the other projects. This will include the following activities: 1) Preparation of standard stocks of HIV-1 and SHIV viral supernatants for neutralization assays. Single-round replication-competent HIV-1 pseudotyped viruses and functional SHIV genomes will be generated by transfecting HEK293 cells. The titers of these viruses will be determined and stocks will be stored for use by this Core and provided to other members of the Program as needed. 2) Performing neutralization assays with human and monkey mAbs and pAbs generated by this program. These antibodies will be tested against parental and modified HIV-1 and SHIVs produced by the Molecular Biology Core. Envs neutralization breadth will be determined against panels of 24 tier 2 subtype B and C pseudoviruses. 3) Mapping the antibody binding epitopes in the envelope proteins of infected monkey sera and monoclonal antibodies. This will be done by performing: a) ELISAs to peptides, fusion proteins and rgp120 proteins, b) neutralization assays with existing (over 200) and newly constructed chimeric or mutant HIV-1 pseudoviruses, c) FACS analysis of cells transfected with selected Envs, d) fractionation of human and monkey sera by affinity adsorption on protein columns. The data generated by this Core will be evaluated and provided to Dr. Pinter and other co-investigators in this program in graphical and tabular forms and analytical reports. These data will be presented on internal teleconferences, scientific meetings and submitted for publications. The experimental procedures to be performed in this core have been routinely used in this laboratory for a number of years, as confirmed by an established record of publications.
This HIVRAD program will involve the generation of viruses and monoclonal and polyclonal antibodies by each of the four participating labs. The availability of a centralized lab to characterize these viruses and antibodies will enhance the uniformity and reproducibility of the data generated by these studies.
|Qualls, Zakiya M; Choudhary, Alok; Honnen, William et al. (2018) Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates. J Virol 92:|
|Perez, Lautaro G; Martinez, David R; deCamp, Allan C et al. (2017) V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS One 12:e0180720|
|Wibmer, Constantinos Kurt; Moore, Penny L; Morris, Lynn (2015) HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS 10:135-43|
|Moore, Penny L; Williamson, Carolyn; Morris, Lynn (2015) Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol 23:204-11|
|Sheward, Daniel J; Ntale, Roman; Garrett, Nigel J et al. (2015) HIV-1 Superinfection Resembles Primary Infection. J Infect Dis 212:904-8|
|Salomon, Aidy; Krachmarov, Chavdar; Lai, Zhong et al. (2014) Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. Virology 448:363-74|
|Derdeyn, Cynthia A; Moore, Penny L; Morris, Lynn (2014) Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS 9:210-6|
|Wibmer, Constantinos Kurt; Bhiman, Jinal N; Gray, Elin S et al. (2013) Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 9:e1003738|
|Sethi, Anurag; Tian, Jianhui; Derdeyn, Cynthia A et al. (2013) A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. PLoS Comput Biol 9:e1003046|
|Murphy, Megan K; Yue, Ling; Pan, Ruimin et al. (2013) Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 9:e1003173|
Showing the most recent 10 out of 15 publications